Infections caused by levofloxacin-sensitive microorganisms: non-hospital pneumonia; complicated skin and soft tissue infections; (for the above-mentioned infections, the drug should only be used when the use of other antibacterial agents that are usually recommended for the initial treatment of these infections is impractical or impossible); complicated urinary tract infections (including pyelonephritis); chronic bacterial prostatitis; pulmonary form of anthrax: prevention after contact and treatment.
Leflocin solution Storage
active substance: levofloxacin;
1 ml of solution contains levofloxacin hemihydrate in terms of 100% substance 5 mg;
Excipients: sodium chloride, disodium edetate, concentrated hydrochloric acid, sodium hydroxide, water for injections.
Leflocin solution Dosage form
Solution for infusion.
Main physical and chemical properties: clear, yellow or greenish-yellow liquid.
Leflocin solution Pharmacotherapeutic group
Antibacterial agents of the quinolone group. Fluoroquinolones. Levofloxacin. ATX code J01M A12.
Leflocin solution Pharmacological properties
Levofloxacin is a synthetic antibacterial agent from the group of fluoroquinolones, the S-enantiomer of a racemic mixture of the drug ofloxacin.
Mechanism of action
As an antibacterial drug from the group of fluoroquinolones, levofloxacin acts on the complex of DNA-DNA gyrase and topoisomerase IV.
Pharmacokinetic / pharmacodynamic ratio
The degree of bacterial activity of levofloxacin depends on the ratio of the maximum serum concentration (Cmax) or the area under the pharmacokinetic curve (AUC) and the minimum inhibitory concentration (MIC).
Mechanism of resistance
Resistance to levofloxacin is acquired in the form of a stepwise process of mutation of the target site in both types of topoisomerase II, DNA ‑ gyrase and topoisomerase IV. Other resistance mechanisms, such as barrier penetration (common with Pseudomonas aeruginosa) and outflow mechanisms, may also affect levofloxacin sensitivity.
Cross-resistance between levofloxacin and other fluoroquinolones has been established.
Due to the mechanism of action, there is usually no cross-resistance between levofloxacin and other classes of antibacterial drugs.
Leflocin® is indicated for the treatment of the following infections in adults (see sections “Features of use” and “Pharmacological properties”):
complicated skin and soft tissue infections;
(for the above infections, the drug should be used only when the use of other antibacterial agents, which are usually recommended for the initial treatment of these infections, is impractical or impossible);
acute pyelonephritis and complicated urinary tract infections (see section “Features”);
chronic bacterial prostatitis;
pulmonary form of anthrax: prevention after contact and treatment (see section “Features”).
Formal recommendations for the proper use of antibacterial agents should be followed.
Hypersensitivity to levofloxacin or to other quinolones, or to any of the excipients;
complaints of side effects from tendons after previous use of quinolones;
children and adolescents;